JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 2784.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Alfresa Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 8.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Alfresa Holdings Corporation’s forward annual dividend is ¥70 per share, paid semi-annual. The forward yield is 2.84% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Alfresa Holdings Corporation’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of ¥31. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alfresa Holdings Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alfresa Holdings Corporation, a Japanese company established in Tokyo in 2003, operates globally through its subsidiaries, specializing in the production, wholesale distribution, marketing, and international trade of pharmaceuticals, diagnostic reagents, and medical equipment. A significant part of its operations involves the wholesale supply of ethical pharmaceuticals, diagnostic reagents, and medical devices to healthcare providers including hospitals, clinics, and dispensing pharmacies. The company also manages the wholesale distribution of self-medication products, such as over-the-counter drugs, nutritional supplements, and health foods, to drugstores and pharmacies. Furthermore, Alfresa is engaged in the manufacturing and commercialization of active pharmaceutical ingredients, various pharmaceuticals, diagnostic reagents, and medical devices, alongside providing contract manufacturing services for pharmaceutical goods. Its medical-related division also encompasses the management of dispensing pharmacies and other associated healthcare activities.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 15, 2025 | ¥10-66.93% vs estimate | ¥698.73B+0.2% vs estimate |
|---|
| Q3 2025 | Feb 10, 2025 | ¥63+29.93% vs estimate | ¥805.97B+4.11% vs estimate |
|---|
| Q2 2025 | Nov 7, 2024 | ¥52+35.12% vs estimate | ¥733.99B-1.54% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥6,651+¥180 (+2.78%)
Takeda Pharmaceutical Company Limited’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
¥3,441+¥67 (+1.99%)
MediPal Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.23% below the high.
¥2,994+¥99 (+3.4%)
Suzuken Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
¥4,004+¥54 (+1.37%)
Toho Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 20.41% below the high.
¥2,576+¥27 (+1.06%)
AS ONE Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.75% below the high.
¥1,545+¥36 (+2.39%)
Vital KSK Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.54% below the high.
¥737+¥6 (+0.82%)
Medius Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 16.63% below the high.
